Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States

David D. Stenehjem, Solomon J. Lubinga, Komal Gupte-Singh, Ying Zhang, Trong Kim Le, John R. Penrod, Cardinale B. Smith

Research output: Contribution to journalArticlepeer-review

Abstract

In this retrospective observational study of nivolumab monotherapy in previously treated advanced non–small-cell lung cancer, overall survival (OS) in real-world patients with good performance status was similar to OS observed in pivotal clinical trials. Poor performance status and tumor programmed death ligand 1 expression < 1% were associated with shorter survival; advanced age had no significant adverse effect on survival.

Original languageEnglish (US)
Pages (from-to)e35-e47
JournalClinical Lung Cancer
Volume22
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Bibliographical note

Funding Information:
This study was supported by Bristol Myers Squibb . D.D.S. reports research funding to his institution from Bristol Myers Squibb , Novartis, AstraZeneca, and Bioverativ , and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals.

Funding Information:
Medical writing assistance was provided by Roland Tacke, PhD, Evidence Scientific Solutions, funded by Bristol Myers Squibb .

Publisher Copyright:
© 2020 The Authors

Keywords

  • Advanced age
  • Observational study
  • Overall survival
  • Performance status
  • Progression-free survival

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States'. Together they form a unique fingerprint.

Cite this